Navigation Links
How the wrong genes are repressed: New finding from UCL
Date:6/11/2010

The mechanism by which 'polycomb' proteins critical for embyronic stem cell function and fate are targeted to DNA has been identified by UCL scientists.

The discovery, which has implications for the fields of stem cell and tissue engineering, is detailed in research published today in the journal Molecular Cell.

A key feature of stem cells is the suppression of genes that when later switched on lead to the differentiation of the cells into specific mature cell types, such as neurons or immune cells. Polycomb proteins, first discovered in fruit flies, are known to play a critical role in the suppression of these developmental genes. PRC2 (polycomb repressive complex-2) is present in all multicellular organisms and has been shown to be important in stem cell differentiation and early embryonic development.

The study authors found that PRC2 is brought to its target genes though binding to a new class of short RNAs transcribed by RNA polymerase II. PRC2 can then methylate chromatin, preventing the activation of developmental regulator genes that would otherwise act to alter the identity of the cell.

Senior author Dr Richard Jenner, UCL Infection & Immunity, said: "We knew that different sets of genes are turned on in different cells and that polycomb proteins prevent the wrong genes from being turned on, for example polycomb prevents the activation of neuronal genes in immune cells. However, although polycomb proteins repress genes, they are actually in a poised state some sort of gene activity seemed to be occurring.

"We wanted to find out what this activity was and our identification of these short RNAs explains this unusual gene state. Discovering that polycomb also binds to these RNAs shows how polycomb might be recruited to genes, which are then repressed to maintain the identities of different cell types. This has been a key question in the field for some time and has important implications for how w
'/>"/>

Contact: Ruth Howells
ruth.howells@ucl.ac.uk
44-207-679-9739
University College London
Source:Eurekalert

Page: 1 2

Related biology news :

1. Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
2. Darwin was wrong about the wild origin of the chicken
3. Study shows Darwin was wrong about the origins of chickens
4. Are existing large-scale simulations of water dynamics wrong?
5. Princeton scientists find way to catalog all that goes wrong in a cancer cell
6. Gene regulation, not just genes, is what sets humans apart
7. Interaction of just 2 genes governs coloration patterns in mice
8. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
9. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
10. Smoking turns on genes -- permanently
11. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
(Date:9/1/2015)... Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... th Annual Global Investment Conference sponsored by ... 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will provide an ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... launch of the new ImageXpress® Micro Confocal High-Content Imaging System. This transformative ... assays that use 3D cellular models such as spheroids, tissues, and organisms. ...
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. , a ... Institutes of Health (NIH) has awarded the company a Phase I Small Business ... Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use this award ...
(Date:9/1/2015)... The Dohmen Company today announced the ... as Chief Science Officer (CSO) of Dohmen Life ... Dr. Floyd will lead Dohmen,s growing regulatory consulting ... and post approval outsourced services in quality, regulatory, ... Floyd brings decades of experience leading global regulatory ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 3AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4